Physician profile
Acklema Mohammad
NPI 1932106291
$34,144.69
in general payments reported to CMS, 2019-2025
12 companies · $1,410 in 2025
The $1,410 reported for 2025 was more than what 98% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,299 · 2020: $4,603 · 2021: $1,282 · 2022: $9,807 · 2023: $8,708 · 2024: $4,036 · 2025: $1,410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,842 · Travel and Lodging: $2,463 · Food and Beverage: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,842.00 |
| Travel and Lodging | $2,463.16 |
| Food and Beverage | $1,848.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $27,834.46 | 2019-2025 | Fasenra, Airsupra |
| Astrazeneca Uk Limited | $2,510.36 | 2023-2025 | Fasenra, Airsupra |
| Astrazeneca Ab | $1,518.81 | 2022 | |
| Glaxosmithkline, LLC. | $996.78 | 2019-2024 | Bexsero, Pediarix, Rotarix |
| Regeneron Healthcare Solutions, INC. | $496.30 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $212.14 | 2019 | |
| Phadia US INC. | $211.43 | 2019-2023 | Immunocap |
| Sobi, INC | $186.00 | 2019-2023 | |
| Sanofi Pasteur INC. | $96.61 | 2021-2024 | |
| Pfizer INC. | $56.13 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $13.21 | 2022 | |
| Circassia INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Acklema Mohammad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.